Providence researchers head to Chicago for leading cancer conference

June 1, 2026 Providence Cancer Institute of Oregon

Researchers at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, are helping shape the future of cancer care at the 2026 ASCO Annual Meeting in Chicago.

This premier event brings together leading oncologists, researchers and health care professionals, who share breakthroughs in cancer immunotherapy, emerging treatments and clinical best practices, including AI platforms to accelerate discovery and personalized care.

Find out which Providence experts are contributing to the 2026 annual meeting and get a glimpse into the studies driving the next wave of cancer research.

Rapid Oral Abstract Sessions

Genitourinary Cancer—Prostate, Testicular, and Penile

Abstract 5018: Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201

Authors: David Page, et al.

Oral Abstract Sessions

Melanoma/Skin Cancers

Abstract 9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.

Authors: Matthew Taylor, et al.

Developmental Therapeutics—Immunotherapy

Abstract 2506: Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors.

Authors: Rom S. Leidner, et al.

Poster Sessions

Head and Neck Cancer

Abstract 6028: Efficacy and safety of pralsetinib in advanced or metastatic RET altered thyroid cancer (TC): Final analysis of the phase 1/2 ARROW study.

Authors: Matthew Taylor, et al.

Developmental Therapeutics—Immunotherapy

Abstract TPS2670: A first-in-human phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of the novel fas ligand (FasL) inhibitor M3T01 in adults with advanced solid tumors

Authors: Rom S. Leidner, Prakash Ambady, Christopher Darus, William Redmond, Bernard A. Fox, Matthew Taylor, et al.

Breast Cancer

Abstract 621: Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy.

Authors: David B. Page, et al.

Abstract 623: Event-free survival from the randomized phase 2 neoHIP trial evaluating neoadjuvant taxane, HER2-targeted therapy, +/- pembrolizumab in early-stage HER2-positive breast cancer

Authors: Alison Conlin, Sasha Stanton, Kelly Perlewitz, David B. Page, et al.

Abstract 1072: A phase 1/2 trial of tersolisib (LY4064809/STX-478), a pan-mutant selective PI3Kα inhibitor (PI3Kαi), in PIK3CA-mutant advanced solid tumors: Updated results from PIKALO-1.

Authors: David B. Page, et al.

Developmental Therapeutics—Immunotherapy

Abstract 2593: Quality of life in cancer patients treated with anchored interleukin-12 (IL-12) immunotherapy: Results from a first-in-human phase 1 trial of tolododekin alfa (ANK-101)

Authors: Brendan Curti, et al.

Genitourinary Cancer—Kidney and Bladder

Abstract 4534: A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic renal cell carcinoma

Authors: Brendan Curti, et al.

Abstract 4535: Combining HC-7366 with belzutifan in patients with renal cell carcinoma to alter tumor and microenvironment: Pharmacokinetic and pharmacodynamic (PK/PD) analysis of a phase 1b study.

Authors: Brendan Curti, et al.

Central Nervous System Tumors

Abstract 2042: Initial analysis of adoptive neoantigen-specific T-cell immunotherapy for MGMT-unmethylated glioblastoma (TVI-AST-008): Signals amid control arm attrition.

Authors: Prakash Ambady, et al.

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Abstract TPS3155: A phase 1/2, first-in-human, open-label, dose-escalation and expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8+ regulatory T cells, in adult patients with locally advanced or metastatic solid tumors

Authors: Rachel E. Sanborn, et al.

Publication Only

Breast Cancer

Abstract e15512: Real-world evaluation of a deep learning–based serial CT imaging biomarker with variable thoracic and abdominopelvic coverage in metastatic colorectal and kidney cancers

Authors: R. Bryan Bell, Brendan Curti, et al.

Abstract e15184: Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid

Authors: Rachel E. Sanborn, et al.

Abstract 20510: PRTH-101: An investigational treatment for thoracic solid tumors targeting discoidin domain receptor (DDR1) and the tumor microenvironment (TME)

Author: Rachel E. Sanborn, et al.

Earle A. Chiles Research Institute and Providence Cancer Institute

Providence Cancer Institute is a leading provider of cancer care in Oregon and a global leader in immuno-oncology. Through its research division, the Earle A. Chiles Research Institute, patients have access to state-of-the-art genomic sequencing, adoptive cellular therapies and a robust clinical research portfolio comprising early phase, investigator-initiated, cooperative group and industry-sponsored trials. Learn more about research at Earle A. Chiles Research Institute.

New guidelines for treating head and neck cancer could be a game changer

Providence receives esteemed NIH grant for ‘paradigm shift’ in head and neck cancer treatments

Welcome to your journey for creating a healthier you

Providence researchers head to Chicago for leading cancer conference

Rapid Oral Abstract Sessions

Oral Abstract Sessions

Poster Sessions

Next Article

Providence researchers head to Chicago for leading cancer conference

Rapid Oral Abstract Sessions

Oral Abstract Sessions

Poster Sessions

Next Article

Most Recent Articles

Three times a week for the past five years, patients, caregivers and visitors at Providence Santa Rosa Memorial Hospital have been delighted and calmed by the site of Jordy.

A $5.4 million gift from Foundation Trustee David Ho and his wife, Martha Ho, is advancing cancer care at Providence Saint John’s Health Center and Saint John’s Cancer Institute through the acquisitio

PSJMC is expanding access to advanced joint replacement care with Mako SmartRobotics, robotic‑assisted technology for partial knee, total knee and total hip replacement

Meet Hany Farid, M.D., a Holy Cross surgeon whose two decades of service reflect the collaboration, compassion and quality that define the hospital’s 65-year story.

Providence Little Company of Mary Medical Center Torrance earns national recognition for the fifth consecutive year, highlighting its commitment to high-quality maternity care.

Inside the IMA203 phase III trial enrolling patients at Providence Cancer Institute.

Discover expert insights, inspiring survivor stories and a powerful celebration of strength and survivorship.

From a 5K training program to free, on‑demand wellness classes such as yoga and strength training, Providence’s Welcome to Basecamp wellness program offers something for everyone.

Providence Little Company of Mary medical centers have earned national recognition for excellence in quality and patient safety, highlighted in the latest Centers for Medicare & Medicaid Services star

Providence Cedars-Sinai Tarzana Medical Center has earned an “A” Hospital Safety Grade from The Leapfrog Group, placing it in the top 32% of hospitals nationwide for patient safety.

How novelty bandages have become a beloved tradition at Providence Cancer Institute Newberg Clinic.

New ASCO guidelines are designed to make the full body of evidence accessible to clinicians across specialties, including those who may not work routinely with a head and neck surgeon.

Providence Mission Hospital has earned Magnet® with Distinction recognition — the highest honor for nursing excellence from the American Nurses Credentialing Center (ANCC).

Providence Sonoma County today announced that Sean Townsend, MD, will join the organization as chief medical officer effective June 1.

Although they have different roles, Maria and Jessica exemplify the compassion and dedication that define our ministry and ease the way of those we serve.

Providence is expanding access to convenient lab services with the opening of our new Eagle River Patient Service Center (PSC) at 12001 Business Blvd. The new location opens Monday, May 11.

Providence Little Company of Mary Medical Center Torrance has once again earned an “A” Hospital Safety Grade from The Leapfrog Group, marking its fourth consecutive rating period.

From the moment patients arrive, their comfort, safety and well‑being depend on systems quietly working in the background; systems that our facilities team monitor around the clock.

2026 DAISY Award Winners at Providence Little Company of Mary Medical Center Torrance.

James Beckerman, M.D., offers helpful tips on KPTV for reducing heart disease risk with easy, consistent actions like short bouts of exercise, proper rest and nutrition.